Discovery of technology platforms: Our cutting edge research has enabled the discovery of preclinical technologies which are functionally and clinically relevant and that can be used to predict treatment outcome with a high degree of accuracy. These sensitive and predictive pre-clinical technologies will lead to better treatment planning for refractory and metastatic cancers (where current response rate is less than 20%) and also for the selection of treatment options for primary cancers where current response rate is 50-60%. These platforms are further useful for the selection and recruitment of patients for the clinical development of new anticancer agents.
 

Novel target discovery: Identifying novel targets for cancer is not new, however, majority of the cases researcher used established cancer cell lines or mouse tumors, as a result those targets do not truly represent human tumors. One of the reasons of not using the patient tumors is the availability of patients. We are in a unique position to lead the discovery of novel targets as we do have access to primary treatment naive and refractory/metastatic human cancers. The outline of our novel targets discovery is described here...

 

Please Contact us for more detail